NTRK3 and gastrointestinal stromal tumor: In addition, one patient with GIST carrying an ETV6-NTRK3 fusion received larotrectinib after five lines of TKIs (case #9 in Table 2) and achieved a partial response (44%) after 4 months of treatment [14].